ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

COGT vs ERAS // RSI-14 & 200D SMA MOMENTUM

Cogent Biosciences Inc. (NASDAQ) VS. Erasca Inc. (NASDAQ) • 15-METRIC TALLY: COGT 3 — ERAS 1
▲ RSI-14 & 200D SMA MOMENTUM LEADER: COGT
rsi-technicals
47.2
rsi-technicals
45.3
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COGT VS. ERAS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC COGT ERAS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -4.80% -1.82% -2.98 ERAS /fcf-yield <GO>
Operating Margin -21.50% — — TIE /operating-margins <GO>
Net Profit Margin -21.20% — — TIE /net-margins <GO>
Revenue Growth (YoY) 22.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 10.84 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 3/9 +2.00 COGT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 47.2 45.3 +1.90 COGT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.05 — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 22.0x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $5.38B $5.02B $363.7M COGT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR COGT REV ERAS REV COGT GROSS % ERAS GROSS % COGT FCF ERAS FCF
FY 2025 $933.4M $394.5M — — -$266.0M -$95.6M
FY 2024 $772.6M $502.8M — — -$208.4M -$109.5M
FY 2023 $582.8M $396.3M — — -$153.6M -$101.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COGT // BETA 1.05
ERAS // BETA —